RESULTS: Overall, 971 (36%) patients underwent RARC and 1,705 (64%) ORC. RARC became the most commonly performed procedure in contemporary patients, with an increase from 14% in 2006-2007 to 58% in 2016-2018 (p<0.001). Patients who underwent RARC were younger than those treated with ORC (median 67 years CONCLUSIONS: The use of RARC is constantly increasing overtaking at these selected centers, ORC. In the last decade perioperative outcomes remained substantially unchanged. We confirmed the lower blood loss and shorter length of stay of RARC compared to ORC. Studies need to reveal whether these quality criteria translate into sustainable long-term quality and quantity of life benefits.
INTRODUCTION AND OBJECTIVES:
Concern has been raised about the oncologic soundness of robot-assisted radical cystectomy (RARC). We present our experience with disease recurrence and metastasis after RARC for bladder cancer.
METHODS: The City of Hope RARC database was queried to identify all patients who underwent RARC for primary urothelial carcinoma of the bladder between 2003 and 2015. Disease recurrences and metastases were categorized by location. The reverse Kaplan-Meier method was used to calculate time to recurrence-or metastasis-free (RMFS) and overall survival (OS). Log rank test was used to compare survival curves. Univariate and multivariate analysis were performed to identify predictors of RMFS and OS.
RESULTS: 379 patients fit the study criteria. The median follow up was 61 months. 97 patients (25.6%) developed recurrence or metastasis during the study period. The most common site of recurrence or metastasis was the pelvis (n[33), followed by the lungs (n[24), retroperitoneum (n[23), bone (n[19) , and liver (n[13). The most distant extent of disease in these patients was locoregional recurrence in 20 patients, retroperitoneal recurrence in 13 patients, distant metastasis in 54 patients, and peritoneal carcinomatosis in 10 patients. 11 of 379 (2.9%) patients had positive surgical margins. 12.4% of patients who did not develop recurrence or metastasis were nodepositive (35/282), compared to 44.3% (43/97) of patients who did develop recurrence or metastasis. 3 year RMFS for <pT2, pT2, pT3, and pT4 disease was 89.9%, 73.3%, 57.6%, and 36.5%, respectively (p<0.0001). 3 year OS for these stages was 86.7%, 61.5%, 40.1%, and 21.5%, respectively (p<0.0001). On multivariate analysis, pathologic T stage and pNþ disease predicted RMFS. American Society of Anesthesiologists score (ASA), pathologic T stage, and pNþ disease predicted OS.
CONCLUSIONS: RARC demonstrates acceptable RMFS and OS across disease stages. Pathologic T stage and pNþ disease predict RMFS and OS after RARC. ASA also predicts OS after RARC. To propose a standardisable composite method for reporting outcomes of radical cystectomy (RC) that incorporates both peri-operative morbidity and oncologic adequacy.
METHODS: From July 2010 through December 2017, 277 consecutive patients who underwent robotic radical cystectomy (RRC) for bladder cancer at our institution were prospectively analysed. IRB approval was obtained (HS-01B014). Patients who simultaneously demonstrated negative soft tissue surgical margins, [/> 16 lymph node yield, absence of major (Clavien-Dindo grade III-IV) complications at 90 days, absence of urinary diversion (UD) related long-term sequelae and absence of clinical recurrence at [/< 12 mo. were considered as having achieved the RC-pentafecta. We created a multivariable logistic regression model using age, ASA score, type of UD, NACH, pT and pN stage as covariates to measure independent factors for achieving RC-pentafecta. The internal validity of the prediction model was assessed by 1,000 bootstrap samples with a two-tailed p-value less than 0.05 being statistically significant. (SPSS 24 Inc., Chicago, IL, USA).
RESULTS: Since 2010, 270 out of 277 patients that had completed at least 12mo. follow-up were included in this analysis. Over a median follow up of 39.5 months, [/> 16 lymph node yield, negative soft surgical margins, absence of major complications at 90 days and absence of UD-related surgical sequelae and clinical recurrence at [/< 12 months were observed in 93.0%, 98.9%, 76.7%, 81.5% and 92.2%, patients, respectively resulting in a RCpentafecta of 53.3% (Fig. a) . When comparing UD, IC was showed higher RC-pentafecta rate (Fig. B) (Fig. C) .
CONCLUSIONS: We present RC-pentafecta as a standardisable composite endpoint that incorporates peri-operative morbidity and oncologic adequacy as a potential tool to assess quality of radical cystectomy. This tool may be useful for assessing learning curve and calculating cost effectiveness amongst others but needs to be externally validated in future studies.
There is some concern that patterns of recurrence after robotic radical cystectomy (RRC) for bladder cancer may vary compared to open radical cystectomy (ORC) due to prolonged pneumoperitoneum and potential cell seeding. Our objective was to compare rates and patterns of recurrence after RRC and intracorporeal urinary diversion (ICUD) compared to ORC.
METHODS: We identified 837 consecutive patients who underwent RRC and ICUD (n[238) or ORC (n[598) from August 2009 to June 2016. All data was collected prospectively within an IRBapproved database and analysed retrospectively. Recurrences were classified as local, distant or secondary urothelial carcinomas. Kaplan-Meier and multivariate Cox regression analysis was performed. A p-value <0.05 was considered statistically significant. RESULTS: Both groups were comparable with respect to age, BMI, ASA, neoadjuvant chemotherapy status, CIS, LVI, positive softtissue margins and node-positive disease (Table 1) . RRC and ICUD patients were more likely to have an ileal conduit (64% vs 29%, p<0.05) and extravesical disease (38% vs 30%, p<0.05). There was no difference in recurrence-free survival for the entire cohort, and by pathological stage: organ-confined disease (pT0-pT2, n[565), extra-vesical disease (pT3-pT4, n[270) and node-positive disease (pNþ, n[183, all p>0 .05) [ Figure 1 ]. Median time to recurrence was 6.9 months in RRC arm and 7.7 months in the ORC arm. On multivariable regression analysis, RRC was not an independent predictor of recurrence after adjusting for confounders (HR 1.05, 95% CI 0.75e1.48; p[0.8) . There were no differences in the number or patterns of recurrences within 2 years, in particular, with respect to peritoneal carcinomatosis and extra-pelvic lymph node metastasis.
CONCLUSIONS: These data show no differences in the rates or patterns of local or distant recurrence between ORC and RRC. The robotic approach is not an independent predictor of recurrence after radical cystectomy for bladder cancer.
